JAGUAR HEALTH, INC. Impairment of Intangible Assets, Finite-lived
JAGUAR HEALTH, INC. (JAGX) reported Impairment of Intangible Assets, Finite-lived of $2.30 million for the 12-month period ending 2017-12-31, per its 10-K filed 2019-04-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2019-04-10
- JAGUAR HEALTH, INC. impairment of intangible assets, finite-lived for fiscal 2017 was $2.30M.
| Period end | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|
| 2017-12-31 | $2.30M 10-K · filed 2019-04-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |